Lymphoma Non-Hodgkin

Inclusion Criteria

- Histologically confirmed diagnosis of indolent B-cell NHL, with histological subtype limited to the following: 
Follicular lymphoma (FL) grade 1-2-3a
Small lymphocytic lymphoma (SLL) with absolute lymphocyte count < 5 x 109/L at the time of diagnosis and at study entry
Lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia (LPL/WM)
Marginal zone lymphoma (MZL) (splenic, nodal, or extra-nodal)
 - Relapsed or refractory after ≥ 2 prior lines of therapy (refractory defined as not responding to a standard regimen or progressing within 6 months of the last course of a standard regimen).  Patients must have previously received rituximab and alkylating agent(s).
 - Japanese patients ≥ 20 years of age
 - ECOG performance status ≤ 2 (Eastern Cooperative Oncology Group:ECOG)
 - Life expectancy of at least 3 months
 - Adequate bone marrow, liver and renal function as assessed within 7 days before starting study treatment
 - Left ventricular ejection fraction (LVEF) ≥ lower limit of normal (LLN) for the Institution
 - Availability of fresh or archival tumor tissue

Exclusion Criteria

- Uncontrolled hypertension (blood pressure ≥ 150/90 mmHg, defined as systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 90 mmHg, despite optimal medical management)
 - Patients with evidence or history of bleeding diathesis.  Any hemorrhage or bleeding event ≥ CTCAE Grade 3 (NCI-CTC version 4.0) within 4 weeks of start of study medication (CTCAE: Common Terminology Criteria for Adverse Events, NCI: National Cancer Institute).
 - History or concurrent condition of interstitial lung disease or severely impaired pulmonary function
 - Unresolved toxicity higher than CTCAE grade 1 attributed to any prior therapy/procedure excluding alopecia. 
 - Prior treatment with PI3K inhibitors
 - Systemic corticosteroid therapy (ongoing) 
 - Type I or II diabetes mellitus with HbA1c > 8.5% or fasting plasma glucose > 160 mg/dL at Screening
 - Known history of human immunodeficiency virus (HIV) infection. 
 - Hepatitis B or C requiring treatment
 - Cytomegalovirus (CMV) PCR positive at baseline
 - Known lymphomatous involvement of the central nervous system